SLC25A25: A Protein Involved in Cellular Signaling and Neurotransmission

Target Name: SLC25A25

NCBI ID: G114789

SLC25A25

SLC25A25: A Protein Involved in Cellular Signaling and Neurotransmission

SLC25A25 (MGC119514) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SLC family of transport proteins, which are known for their ability to transport a wide variety of molecules across cell membranes. SLC25A25 is specifically known for its role in the transport of nucleotides, such as DNA and RNA, across cell membranes.

SLC25A25 is a protein that is expressed in the brain, where it is found in the basal ganglia, which is a network of brain cells that is responsible for controlling movement and other functions. The basal ganglia is also home to the dopamine system, which is a complex system of neurons that is responsible for the mood, appetite, and other functions that are controlled by the brain. SLC25A25 is thought to be involved in the regulation of the movement of neurons in the basal ganglia, and it is possible that it may be a drug target or biomarker for a variety of neurological and psychiatric conditions.

SLC25A25 is also expressed in the heart and kidneys, and it is thought to play a role in the regulation of ion transport in these tissues. The heart is responsible for pumping blood throughout the body, and the kidneys are responsible for filtering waste products from the blood and removing excess water and electrolytes. SLC25A25 may be involved in the regulation of the ion transport that is required for the proper functioning of the heart and kidneys.

In addition to its role in transport across cell membranes, SLC25A25 is also known for its role in the regulation of cellular signaling processes. The signaling processes that occur within cells are critical for the development and maintenance of tissues and organs, and SLC25A25 is thought to be involved in these processes. For example, SLC25A25 has been shown to be involved in the regulation of the levels of neurotransmitters, such as dopamine and GABA, in the brain.

SLC25A25 is also a potential biomarker for a variety of neurological and psychiatric conditions. For example, studies have shown that SLC25A25 is often reduced in the brains of individuals with Alzheimer's disease, a condition that is characterized by the progressive loss of brain cells that are responsible for memory and other cognitive functions. Additionally, SLC25A25 has been shown to be involved in the regulation of the levels of certain signaling molecules in the brains of individuals with Parkinson's disease, a condition that is characterized by the progressive loss of brain cells that are responsible for movement and other functions.

In conclusion, SLC25A25 is a protein that is expressed in various tissues of the body and is involved in the regulation of a wide variety of cellular processes. It is also thought to be involved in the regulation of the movement of neurons in the basal ganglia and in the regulation of ion transport in the heart and kidneys. Additionally, SLC25A25 is a potential biomarker for a variety of neurological and psychiatric conditions and may be a drug target for the development of new treatments for these conditions. Further research is needed to fully understand the role of SLC25A25 in the regulation of cellular processes and its potential as a drug target or biomarker.

Protein Name: Solute Carrier Family 25 Member 25

Functions: Electroneutral antiporter that most probably mediates the transport of adenyl nucleotides through the inner mitochondrial membrane. Originally identified as an ATP-magnesium/inorganic phosphate antiporter, it could have a broader specificity for adenyl nucleotides. By regulating the mitochondrial matrix adenyl nucleotide pool could adapt to changing cellular energetic demands and indirectly regulate adenyl nucleotide-dependent metabolic pathways

The "SLC25A25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets